The FDA report on intraocular lenses

W. J. Stark, D. M. Worthen, J. T. Holladay, P. E. Bath, M. E. Jacobs, G. C. Murray, E. T. McGhee, M. W. Talbott, M. D. Shipp, N. E. Thomas, R. W. Barnes, D. W. Brown, J. N. Buxton, R. D. Reinecke, C. S. Lao, S. Fisher

Research output: Contribution to journalArticle

Abstract

Clinical studies of intraocular lenses (IOLs) as investigational devices have been regulated in the United States by the Food and Drug Administration (FDA) since February 9, 1978. As of August 1982, data have been collected on more than one million IOLs implanted. During the last 12 months of the study, 409,000 IOLs were implanted. Visual acuity of 20/40 or better at one year after surgery was present in 85% of over 45,000 cases reviewed. Increasing patient age, surgical problems, postoperative complications, and adverse reactions were factors that reduced the visual acuity. The current trend in the USA is for implantation of the posterior chamber and anterior chamber IOLs.

Original languageEnglish (US)
Pages (from-to)311-317
Number of pages7
JournalOphthalmology
Volume90
Issue number4
StatePublished - 1983

Fingerprint

Intraocular Lenses
United States Food and Drug Administration
Visual Acuity
Anterior Chamber
Equipment and Supplies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Stark, W. J., Worthen, D. M., Holladay, J. T., Bath, P. E., Jacobs, M. E., Murray, G. C., ... Fisher, S. (1983). The FDA report on intraocular lenses. Ophthalmology, 90(4), 311-317.

The FDA report on intraocular lenses. / Stark, W. J.; Worthen, D. M.; Holladay, J. T.; Bath, P. E.; Jacobs, M. E.; Murray, G. C.; McGhee, E. T.; Talbott, M. W.; Shipp, M. D.; Thomas, N. E.; Barnes, R. W.; Brown, D. W.; Buxton, J. N.; Reinecke, R. D.; Lao, C. S.; Fisher, S.

In: Ophthalmology, Vol. 90, No. 4, 1983, p. 311-317.

Research output: Contribution to journalArticle

Stark, WJ, Worthen, DM, Holladay, JT, Bath, PE, Jacobs, ME, Murray, GC, McGhee, ET, Talbott, MW, Shipp, MD, Thomas, NE, Barnes, RW, Brown, DW, Buxton, JN, Reinecke, RD, Lao, CS & Fisher, S 1983, 'The FDA report on intraocular lenses', Ophthalmology, vol. 90, no. 4, pp. 311-317.
Stark WJ, Worthen DM, Holladay JT, Bath PE, Jacobs ME, Murray GC et al. The FDA report on intraocular lenses. Ophthalmology. 1983;90(4):311-317.
Stark, W. J. ; Worthen, D. M. ; Holladay, J. T. ; Bath, P. E. ; Jacobs, M. E. ; Murray, G. C. ; McGhee, E. T. ; Talbott, M. W. ; Shipp, M. D. ; Thomas, N. E. ; Barnes, R. W. ; Brown, D. W. ; Buxton, J. N. ; Reinecke, R. D. ; Lao, C. S. ; Fisher, S. / The FDA report on intraocular lenses. In: Ophthalmology. 1983 ; Vol. 90, No. 4. pp. 311-317.
@article{a06cb3a4124d43389b8e13e6552289b2,
title = "The FDA report on intraocular lenses",
abstract = "Clinical studies of intraocular lenses (IOLs) as investigational devices have been regulated in the United States by the Food and Drug Administration (FDA) since February 9, 1978. As of August 1982, data have been collected on more than one million IOLs implanted. During the last 12 months of the study, 409,000 IOLs were implanted. Visual acuity of 20/40 or better at one year after surgery was present in 85{\%} of over 45,000 cases reviewed. Increasing patient age, surgical problems, postoperative complications, and adverse reactions were factors that reduced the visual acuity. The current trend in the USA is for implantation of the posterior chamber and anterior chamber IOLs.",
author = "Stark, {W. J.} and Worthen, {D. M.} and Holladay, {J. T.} and Bath, {P. E.} and Jacobs, {M. E.} and Murray, {G. C.} and McGhee, {E. T.} and Talbott, {M. W.} and Shipp, {M. D.} and Thomas, {N. E.} and Barnes, {R. W.} and Brown, {D. W.} and Buxton, {J. N.} and Reinecke, {R. D.} and Lao, {C. S.} and S. Fisher",
year = "1983",
language = "English (US)",
volume = "90",
pages = "311--317",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - The FDA report on intraocular lenses

AU - Stark, W. J.

AU - Worthen, D. M.

AU - Holladay, J. T.

AU - Bath, P. E.

AU - Jacobs, M. E.

AU - Murray, G. C.

AU - McGhee, E. T.

AU - Talbott, M. W.

AU - Shipp, M. D.

AU - Thomas, N. E.

AU - Barnes, R. W.

AU - Brown, D. W.

AU - Buxton, J. N.

AU - Reinecke, R. D.

AU - Lao, C. S.

AU - Fisher, S.

PY - 1983

Y1 - 1983

N2 - Clinical studies of intraocular lenses (IOLs) as investigational devices have been regulated in the United States by the Food and Drug Administration (FDA) since February 9, 1978. As of August 1982, data have been collected on more than one million IOLs implanted. During the last 12 months of the study, 409,000 IOLs were implanted. Visual acuity of 20/40 or better at one year after surgery was present in 85% of over 45,000 cases reviewed. Increasing patient age, surgical problems, postoperative complications, and adverse reactions were factors that reduced the visual acuity. The current trend in the USA is for implantation of the posterior chamber and anterior chamber IOLs.

AB - Clinical studies of intraocular lenses (IOLs) as investigational devices have been regulated in the United States by the Food and Drug Administration (FDA) since February 9, 1978. As of August 1982, data have been collected on more than one million IOLs implanted. During the last 12 months of the study, 409,000 IOLs were implanted. Visual acuity of 20/40 or better at one year after surgery was present in 85% of over 45,000 cases reviewed. Increasing patient age, surgical problems, postoperative complications, and adverse reactions were factors that reduced the visual acuity. The current trend in the USA is for implantation of the posterior chamber and anterior chamber IOLs.

UR - http://www.scopus.com/inward/record.url?scp=0020536626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020536626&partnerID=8YFLogxK

M3 - Article

VL - 90

SP - 311

EP - 317

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 4

ER -